Somatostatin receptor expression in Hurthle cell cancer of the thyroid

Seza A. Gulec, Aldo N. Serafini, Kasi S. Sridhar, Kamil R. Peker, Anurag Gupta, W. Jarrard Goodwin, George N. Sfakianakis, Frederick L. Moffat

Research output: Contribution to journalArticlepeer-review

33 Scopus citations


Somatostatin receptor expression, which was not a previously described marker for Hurthle cell cancer of the thyroid, was demonstrated by in vivo imaging with 111In-pentetreotide in three patients. This phenomenon not only adds another imaging technique to the nuclear medicine armamentarium for detecting recurrent and metastatic cancer in patients with Hurthle cell cancer but also opens up an alternative therapeutic avenue with somatostatin analogs or their radiolabeled compounds.

Original languageEnglish (US)
Pages (from-to)243-245
Number of pages3
JournalJournal of Nuclear Medicine
Issue number2
StatePublished - Feb 1998


  • Hurthle cell cancer
  • Indium-111- pentetreotide
  • Somatostatin receptors
  • Thyroid cancer

ASJC Scopus subject areas

  • Radiological and Ultrasound Technology


Dive into the research topics of 'Somatostatin receptor expression in Hurthle cell cancer of the thyroid'. Together they form a unique fingerprint.

Cite this